Conditions: Parkinson Disease Multiple System Atrophy
Keywords: Parkinson disease Multiple system atrophy Intranasal Insulin
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 15
Healthy volunteers: no

Brief summary:
Parkinson disease (PD) and multiple system atrophy (MSA) are progressive neurodegenerative disorders characterized by abnormal accumulation of α-synuclein. There is no effective treatment that can slow down the disease progression and both disorders are associated with severe cognitive decline. It was shown that intranasal insulin (INI) improves learning and memory in healthy and cognitively impaired non-diabetic adults.

The proof-of-concept, randomized, placebo-controlled, cross-over pilot study ( NCT01206322) has shown that a single 40 international units dose of intranasal insulin improves visuospatial memory in diabetes and control subjects.

This proposal includes randomized, double blinded, placebo-controlled trial of intranasal insulin (40 international units daily) in treatment of PD and MSA.

The study will evaluate 22 patients with PD and 22 patients with MSA. Total duration of the study will be 2 years. The primary goal is to assess the efficacy of INI in treatment of cognitive abnormalities in both PD and MSA. The primary efficacy end point will be change of the cognitive scale ratings.

Detailed description:

Arms:
arm 1: 40 IU of intranasal insulin daily arm 2: Placebo arm using intranasal normal saline

Interventions: intervention 1: Intranasal Insulin
Intervention descriptions: intervention 1: 1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;
2. placebo arm: normal saline, daily, intranasally, for 4 weeks.

Protocol document: